citr annual report exhibits
DESCRIPTION
CITR Annual Report Exhibits. 2007 CITR Annual Report Exhibits Prepared by: CITR Coordinating Center The EMMES Corporation Rockville, MD Sponsored by: National Institute of Diabetes & Digestive & Kidney Diseases National Institutes of Health Bethesda, MD Datafile Closure: April 1, 2007. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/1.jpg)
CITR Annual Report Exhibits2007 CITR Annual ReportExhibits
Prepared by:
CITR Coordinating CenterThe EMMES Corporation
Rockville, MD
Sponsored by:National Institute of Diabetes & Digestive & Kidney Diseases
National Institutes of HealthBethesda, MD
Datafile Closure: April 1, 2007
![Page 2: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/2.jpg)
Table of Contents
Chapter 1: Islet Transplant Activity
Chapter 2: Recipient and Donor Characteristics
Chapter 3: Pancreas Procurement, Islet Processing and Infusion
Characteristics
Chapter 4: Immunosuppression and Other Medications
Chapter 5: Graft Function
Chapter 6: Liver, Kidney, Lipid and PRA Effects
Chapter 7: Adverse Events
Chapter 8: Registry Data Quality Review
CITR Coordinating Center
CITR Committees
![Page 3: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/3.jpg)
Chapter 1: Islet Transplant Activity
![Page 4: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/4.jpg)
Islet Transplant Centers Reporting Data to CITR:Participating North American Centers 1999-2006
A - CITR Centers with at least one islet allograft infusion procedure conducted in 2006C - CITR Centers with no islet allograft infusions in 2006D - CITR Coordinating Center
![Page 5: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/5.jpg)
Number of Islet Transplantation Centers Performing Islet Allografts per Year
and Number with Data Entered in CITR Database All North American Islet Transplant Centers 1999-2006
All North American Centers Performing Islet Allografts (N=31)CITR-Participating Centers with Data Entered (N=24)
6
3
9
6
16
11
14
10
20
15
23
1716
14
Num
ber o
f Cen
ters
0
5
10
15
20
25
1999-2000 2001 2002 2003 2004 2005 2006
![Page 6: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/6.jpg)
Total Number of Islet Transplant Recipients, Recipients at CITR-Participating Centers,
and Recipients with Detailed Data Reported to CITR By Year of First Islet Allograft Infusion
All North American Islet Transplant Centers 1999-2006
The Islet Transplant Summary (ITS) questionnaire is completed by all North American Islet Transplant Programs regardless of their participation in the Registry. Of 45 North American islet transplant programs polled, all have provided this information through 2006.
All North American Recipients (N=356)All North American CITR Recipients (N=315)Recipients with Detailed Data Reported to CITR (N=268)
31 31
16
45 44
35
82
75
69
45
3835
53
42 40
64
54
44
3631 29N
umbe
r of R
ecip
ient
s
0
10
20
30
40
50
60
70
80
90
1999-2000 2001 2002 2003 2004 2005 2006
![Page 7: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/7.jpg)
Total Number of Islet Allograft Infusion Procedures Performed and Number with Data Reported to CITR:
CITR-Participating North American Islet Transplant Centers 1999-2006
All Infusions for North American Recipients (N=675)All Infusions for North American CITR Recipients (N=596)Infusions with Data Reported to CITR (N=512)
50 50
32
65 64
49
142132
119
106
9183
110
89 85
124
106
8878
6456
Num
ber o
f Pro
cedu
res
0
20
40
60
80
100
120
140
160
1999-2000 2001 2002 2003 2004 2005 2006
![Page 8: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/8.jpg)
Total Number (N=579) of Islet Allograft Infusion Procedures Conducted and Entered in CITR Database, by Year and Infusion Procedure Number:
CITR-Participating North American and International Centers, 1999-2006
First infusionSecond InfusionThird InfusionFourth Infusion
38
49
119
9298
107
71
5
Num
ber o
f Isl
et In
fusi
ons
0
15
30
45
60
75
90
105
120
1999-2000 2001 2002 2003 2004 2005 2006 2007
![Page 9: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/9.jpg)
Total Number (N=579) of Islet Allograft Infusion Procedures Per Recipient:
CITR-Participating North American and International Centers, 1999-2006
76
149
63
4
Num
ber o
f Rec
ipie
nts
0
20
40
60
80
100
120
140
160
Total Number of Infusions Received
1 2 3 4
![Page 10: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/10.jpg)
Islet Alone and Islet After Kidney Recipients:CITR-Participating North American and International Centers,
1999-2006
SUM of value by type
Islet Alone262
Islet After Kidney30
![Page 11: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/11.jpg)
Chapter 2: Recipient and Donor Characteristics
![Page 12: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/12.jpg)
Recipient Demographics
![Page 13: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/13.jpg)
Transplant Recipient Primary Funding InformationCITR-Participating US Centers
![Page 14: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/14.jpg)
Recipient Characteristics at First Infusion
![Page 15: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/15.jpg)
Recipient Diabetes Characteristics at First Infusion
![Page 16: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/16.jpg)
Recipient Diabetes Characteristics at First Infusion (continued)
![Page 17: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/17.jpg)
Recipient Infectious Disease Testing at First Infusion
![Page 18: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/18.jpg)
Recipient Characteristics at First Infusion by Total Number of Infusions Received
![Page 19: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/19.jpg)
Recipient Demographics and Characteristics at First Infusionby Total Number of Infusions Received
![Page 20: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/20.jpg)
Recipient Laboratory Values at First Infusion
![Page 21: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/21.jpg)
Donor DemographicsAll Allograft Donors
![Page 22: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/22.jpg)
Donor CharacteristicsAll Allograft Donors
![Page 23: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/23.jpg)
Donor CharacteristicsAll Allograft Donors (continued)
![Page 24: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/24.jpg)
Characteristics of Organ Procurement and Donor Cause of DeathAll Allograft Donors
![Page 25: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/25.jpg)
Treatments Given to Donor During HospitalizationAll Allograft Donors
![Page 26: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/26.jpg)
Treatments Given to Donor During HospitalizationAll Allograft Donors (continued)
![Page 27: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/27.jpg)
Donor SerologyAll Allograft Donors
![Page 28: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/28.jpg)
Donor Laboratory DataAll Allograft Donors
![Page 29: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/29.jpg)
Organ Crossmatch ResultsAll Allograft Donors
![Page 30: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/30.jpg)
Chapter 3: Pancreas Procurement, Islet Processing and Infusion Characteristics
![Page 31: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/31.jpg)
Pancreas Procurement and Islet Processing
![Page 32: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/32.jpg)
Pancreas Procurement and Islet Processing (continued)
![Page 33: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/33.jpg)
Pancreas Procurement and Islet Processing (continued)
![Page 34: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/34.jpg)
Cold Ischemia Information
![Page 35: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/35.jpg)
Islet Equivalents and Timing of Count
![Page 36: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/36.jpg)
Islet Product Characterization
![Page 37: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/37.jpg)
Islet Characteristics by Pancreas Preservation Method
![Page 38: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/38.jpg)
Correlation of Islet Characteristics with Donor, Recovery, and Processing Characteristics
![Page 39: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/39.jpg)
Islet Product and Infusion Characteristics by Infusion Sequence
![Page 40: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/40.jpg)
Mean Number of Islet Equivalents/Kg Recipient by Total Number of Infusions Received
![Page 41: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/41.jpg)
Pre Infusion Portal Pressure by Infusion Sequence
233 167 45
1 2 3
0
5
10
15
20
25
30
mm
Hg
Infusion Sequence
![Page 42: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/42.jpg)
Peak Portal Pressure by Infusion Sequence
223 165 45
1 2 3
0
5
10
15
20
25
30
mm
Hg
Infusion Sequence
![Page 43: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/43.jpg)
Closure Portal Pressure by Infusion Sequence
228 165 46
1 2 3
0
5
10
15
20
25
30
mm
Hg
Infusion Sequence
![Page 44: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/44.jpg)
Change from Pre Infusion to Closure Portal Pressure by Infusion Sequence
226 164 45
1 2 3
-10
-5
0
5
10
15
20
mm
Hg
Infusion Sequence
![Page 45: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/45.jpg)
Change from Pre Infusion to Peak Portal Pressure by Infusion Sequence
223 164 44
1 2 3
-10
-5
0
5
10
15
20
mm
Hg
Infusion Sequence
![Page 46: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/46.jpg)
Cell Volume Infused per Infusion by Infusion Year
14 23 47 109 85 83 97 62
1999 2000 2001 2002 2003 2004 2005 2006
0.0
2.0
4.0
6.0
8.0
10.0
12.0
14.0
16.0
Cel
l Vol
ume
(mL)
Infusion Year
![Page 47: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/47.jpg)
Chapter 4: Immunosuppression and Other Medications
![Page 48: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/48.jpg)
Immunosuppression Regimen at Time of First Infusion
![Page 49: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/49.jpg)
Immunosuppression Regimen at Time of First Infusion (continued)
![Page 50: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/50.jpg)
T Cell Antibodies Used During First Infusion for Induction Therapy
![Page 51: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/51.jpg)
Anti-inflammatory Therapy at Time of Infusion by Infusion Sequence
![Page 52: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/52.jpg)
Immunosuppression Dosing (mg/day) at Time of Infusion by Infusion Sequence
![Page 53: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/53.jpg)
Immunosuppression Therapy Use Post Last Infusion
![Page 54: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/54.jpg)
Immunosuppression Therapy Use Post Last Infusion (continued)
![Page 55: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/55.jpg)
Immunosuppression Dosing Post Last Infusion
![Page 56: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/56.jpg)
Immunosuppression Dosing Post Last Infusion (continued)
![Page 57: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/57.jpg)
Sirolimus Trough Level (ng/mL) Post Last InfusionAll Allograft Recipients
225 171 48 157 124 70 43
Inf 1Day 30
Inf 2Day 30
Inf 3Day 30
Month 6 Year 1 Year 2 Year 3
0.00
10.00
20.00
30.00
40.00
50.00
Siro
limus
Tro
ugh
(ng/
mL)
Follow -Up
*Value of 61.8 ng/mL at Inf 3 Day 30 excluded from display.
Verified correct by center, attributed to the participant taking Sirolimus shortly before sampling.
![Page 58: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/58.jpg)
Tacrolimus Trough Level (ng/mL) Post Last InfusionAll Allograft Recipients
228 174 52 164 137 85 52
Inf 1Day 30
Inf 2Day 30
Inf 3Day 30
Month 6 Year 1 Year 2 Year 3
0.00
5.00
10.00
15.00
20.00
Tacr
olim
us T
roug
h (n
g/m
L)
Follow -Up
![Page 59: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/59.jpg)
Anti-Hypertensive Medications Pre Infusion and Post Last Infusion
All Allograft Recipients
![Page 60: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/60.jpg)
Total Number of Anti-Hypertensive Medications Pre Infusion and Post Last Infusion
All Allograft Recipients
Total Number of Medications 4321
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
![Page 61: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/61.jpg)
Lipid Lowering Medications Pre Infusion and Post Last Infusion
All Allograft Recipients
![Page 62: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/62.jpg)
Total Number of Lipid Lowering MedicationsPre Infusion and Post Last Infusion
All Allograft Recipients
Total Number of Medications 21
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
![Page 63: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/63.jpg)
Adjunctive Therapy Used at Time of First InfusionAll Allograft Recipients
Vitamins
Rosiglitizone
Pioglitazone
Pentoxifyl l ine
Pantoprazole
Ondansetron Hydrochloride
Nicotinamide
Metformin
Iron Supplements
Enoxaparin
Aspirin
Antivirals
Antifungals
Antibiotics
Percent of Recipients
0 10 20 30 40 50 60 70 80 90 100
![Page 64: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/64.jpg)
Adjunctive Therapy Post Last InfusionAll Allograft Recipients
![Page 65: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/65.jpg)
Chapter 5: Graft Function
![Page 66: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/66.jpg)
Insulin Independence, Insulin Dependence, Absence of Fasting C-peptide, or Re-Infusion
Post First InfusionA. Islet Alone Recipients
Recipient Status Re-Infused Prior to Follow-UpInsulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Day 30N=262
Day 75*N=262
Month 6N=255
Year 1N=244
Year 3**N=152
*C-peptide data not available at Day 75
**Year 3 status independent of re-infusion
![Page 67: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/67.jpg)
Insulin Independence, Insulin Dependence, Absence of Fasting C-peptide, or Re-Infusion
Post First Infusion B. Islet After Kidney Recipients
Recipient Status Re-Infused Prior to Follow-UpInsulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Day 30N=30
Day 75*N=30
Month 6N=29
Year 1N=26
Year 3**N=20
*C-peptide data not available at Day 75
**Year 3 status independent of re-infusion
![Page 68: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/68.jpg)
Insulin Independence, Insulin Dependence or Absence of Fasting C-peptide
Post Last Infusion A. Islet Alone Recipients
Recipient Status Insulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 69: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/69.jpg)
Insulin Independence, Insulin Dependence or Absence of Fasting C-peptide
Post Last InfusionB. Islet After Kidney Recipients
Recipient Status Insulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 70: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/70.jpg)
Insulin Independence, Insulin Dependence, or Absence of Fasting C-peptide
Post Last Infusion by Total Number of Infusions ReceivedIslet Alone Recipients
A. Recipients of 1 Infusion
Recipient Status Insulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
Month 6N=63
Year 1N=56
Year 2N=39
Year 3N=33
![Page 71: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/71.jpg)
Insulin Independence, Insulin Dependence, or Absence of Fasting C-peptide
Post Last Infusion by Total Number of Infusions ReceivedIslet Alone Recipients
A. Recipients of 2 Infusions
Recipient Status Insulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
Month 6N=129
Year 1N=117
Year 2N=88
Year 3N=66
![Page 72: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/72.jpg)
Insulin Independence, Insulin Dependence, or Absence of Fasting C-peptide
Post Last Infusion by Total Number of Infusions ReceivedIslet Alone Recipients
A. Recipients of 3 Infusions
Recipient Status Insulin IndependentInsulin Dependent with Detectable Fasting C-peptideNo Detectable Fasting C-peptideMissing Data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
Month 6N=57
Year 1N=52
Year 2N=42
Year 3N=30
![Page 73: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/73.jpg)
Prevalence of Insulin Independence Post Last InfusionIslet Alone Recipients
Best Case Reported Worst Case
Perc
ent I
nsul
in In
depe
nden
t
0
10
20
30
40
50
60
70
Days Post Last Infusion
0 100 200 300 400 500 600 700 800 900 1000 1100
![Page 74: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/74.jpg)
Prevalence of Insulin Independence Post Last Infusion By Total Number of Infusions Received
Islet Alone Recipients
Total Number of Infusions Received One Two Three
Perc
ent I
nsul
in In
depe
nden
t
0
10
20
30
40
50
60
70
Days Post Last Infusion
0 100 200 300 400 500 600 700 800 900 1000 1100
![Page 75: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/75.jpg)
HbA1C A. Post First Infusion (Censored at Re-Infusion before Visit)
Islet Alone Recipients
HbA1c < 6.5%6.5% <= HbA1c < 7.0%HbA1c >= 7.0%Missing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Inf 1N=262
Month 6N=110
Year 1N=76
![Page 76: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/76.jpg)
HbA1C Post First Infusion (Censored at Re-Infusion before Visit)
Islet After Kidney Recipients
HbA1c < 6.5%6.5% <= HbA1c < 7.0%HbA1c >= 7.0%Missing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Inf 1N=30
Month 6N=12
Year 1N=7
![Page 77: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/77.jpg)
HbA1CB. Post Last InfusionIslet Alone Recipients
HbA1c < 6.5%6.5% <= HbA1c < 7.0%HbA1c >= 7.0%Missing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Inf 1N=262
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 78: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/78.jpg)
HbA1CB. Post Last Infusion
Islet After Kidney Recipients
HbA1c < 6.5%6.5% <= HbA1c < 7.0%HbA1c >= 7.0%Missing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
Pre Inf 1N=30
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 79: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/79.jpg)
C-peptide 0.5 ng/mLA. Post First Infusion (Censored at Re-Infusion before Visit)
Islet Alone Recipients
C-peptide < 0.5 ng/mLC-peptide >= 0.5 ng/mLMissing data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
Pre Inf 1N=262
Month 6N=110
Year 1N=76
![Page 80: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/80.jpg)
C-peptide 0.5 ng/mLA. Post First Infusion (Censored at Re-Infusion before Visit)
Islet After Kidney Recipients
C-peptide < 0.5 ng/mLC-peptide >= 0.5 ng/mLMissing data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
Pre Inf 1N=30
Month 6N=12
Year 1N=7
![Page 81: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/81.jpg)
C-peptide 0.5 ng/mLB. Post Last InfusionIslet Alone Recipients
C-peptide < 0.5 ng/mLC-peptide >= 0.5 ng/mLMissing data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
Pre Inf 1N=262
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 82: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/82.jpg)
C-peptide 0.5 ng/mLB. Post Last Infusion
Islet After Kidney Recipients
C-peptide < 0.5 ng/mLC-peptide >= 0.5 ng/mLMissing data
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
Pre Inf 1N=30
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 83: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/83.jpg)
Severe HypoglycemiaA. Post First Infusion (Censored at Re-Infusion before Visit)
Islet Alone Recipients
No severe hypoglycemic episodesSevere hypoglycemic episodeMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=262
Month 6N=47
Year 1N=20
![Page 84: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/84.jpg)
Severe HypoglycemiaB. Post First Infusion (Censored at Re-Infusion before Visit)
Islet After Kidney Recipients
No severe hypoglycemic episodesSevere hypoglycemic episodeMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=30
Month 6N=5
Year 1N=2
![Page 85: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/85.jpg)
Severe HypoglycemiaC. Post Last Infusion Islet Alone Recipients
No severe hypoglycemic episodesSevere hypoglycemic episodeMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=262
Day 30N=262
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 86: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/86.jpg)
Severe HypoglycemiaD. Post Last Infusion
Islet After Kidney Recipients
No severe hypoglycemic episodesSevere hypoglycemic episodeMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=30
Day 30N=30
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 87: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/87.jpg)
Severe HypoglycemiaE. Post Last Infusion
Islet Alone Recipients with Detectable Fasting C-peptide
Severe hypoglycemic episodeMissing data
Per
cent
of R
ecip
ient
s
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=92
Day 30N=254
Month 6N=219
Year 1N=177
Year 2N=115
Year 3N=75
![Page 88: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/88.jpg)
Severe HypoglycemiaF. Post Last Infusion
Islet Alone Recipients without Detectable Fasting C-peptide
Severe hypoglycemic episodeMissing data
Per
cent
of R
ecip
ient
s
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=170
Day 30N=8
Month 6N=30
Year 1N=48
Year 2N=54
Year 3N=54
![Page 89: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/89.jpg)
Hypoglycemia Status Pre First Infusion and Post Last Infusion
All Allograft Recipients
No hypoglycemic episodesHaving episodes and awarePartial awarenessHypoglycemia unawarenessMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
Pre Inf 1N=292
Month 6N=277
Year 1N=250
Year 2N=192
Year 3N=140
![Page 90: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/90.jpg)
Graft Loss or Dysfunction Post Last InfusionA. Islet Alone Recipients
Complete Graft FailureIslet Graft Dysfunction
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
Day 30N=262
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 91: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/91.jpg)
Graft Loss or Dysfunction Post Last InfusionB. Islet After Kidney Recipients
Complete Graft FailureIslet Graft Dysfunction
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
Day 30N=30
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 92: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/92.jpg)
Persistence of Islet Graft Function (IA, IAK)
![Page 93: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/93.jpg)
Persistence of Islet Graft Function by Ever Achieving Insulin Independence
Islet Alone RecipientsNot Censored at Re-Infusion
![Page 94: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/94.jpg)
Achievement of Insulin IndependenceA. All Allograft Recipients
Post First Infusion (Not Censored at Re-Infusion)
Days Post First Infusion
Type of AllograftIslet Alone
Islet After Kidney
![Page 95: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/95.jpg)
Achievement of Insulin IndependenceB. Islet Alone Recipients
Post First Infusion (Censored at Re-Infusion)
![Page 96: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/96.jpg)
Achievement of Insulin IndependenceC. Islet Alone Recipients
Post Second Infusion (Recipients Not Insulin Independent after First Infusion,
Censored at Third Infusion)
N 158 76 54 46 35
Days Post Second Infusion
![Page 97: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/97.jpg)
Achievement of Insulin IndependenceD. Islet Alone Recipients
Post Third Infusion (Recipients Not Insulin Independent after First or Second Infusion,
Censored at Fourth Infusion)
Perc
ent
of R
ecip
ient
s
0
10
20
30
40
50
60
70
80
90
100
Days Post Third Infusion
0 25 50 75 100 125 150 175 200
N 40 20 13 12 12
![Page 98: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/98.jpg)
Persistence of Insulin Independence and Persistence of Graft Function
Islet Alone Recipients Achieving Insulin IndependenceNot Censored at Re-Infusion
![Page 99: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/99.jpg)
Persistence of Insulin IndependenceBy Total Number of Infusions Given Prior to
Achievement of Insulin IndependenceIslet Alone Recipients Achieving Insulin Independence
![Page 100: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/100.jpg)
Composite Outcome (Hypoglycemia and HbA1C) Post Last Infusion
A. Islet Alone Recipients
No severe hypoglycemic episodes and HbA1c < 6.5%No severe hypoglycemic episodes and 6.5% <= HbA1c < 7.0%Severe hypoglycemic episode or HbA1c >= 7.0% with detectable fasting c-peptideSevere hypoglycemic episode or HbA1c >= 7.0% without detectable fasting c-peptideMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
Pre Infusion 1N=262
Day 30N=262
Month 6N=249
Year 1N=225
Year 2N=169
Year 3N=129
![Page 101: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/101.jpg)
Composite Outcome (Hypoglycemia and HbA1C) Post Last Infusion
B. Islet After Kidney Recipients
No severe hypoglycemic episodes and HbA1c < 6.5%No severe hypoglycemic episodes and 6.5% <= HbA1c < 7.0%Severe hypoglycemic episode or HbA1c >= 7.0% with detectable fasting c-peptideSevere hypoglycemic episode or HbA1c >= 7.0% without detectable fasting c-peptideMissing data for recipient without islet graft functionMissing data for recipient with islet graft function
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
Pre Infusion 1N=30
Day 30N=30
Month 6N=28
Year 1N=25
Year 2N=23
Year 3N=11
![Page 102: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/102.jpg)
Average Daily Insulin (Units) Taken By Recipients on Insulin Baseline and Post Last Infusion
A. Islet Alone Recipients
233 48 48 31 30
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
0.0
20.0
40.0
60.0
80.0
100.0A
vera
ge D
aily
Insu
lin U
se (U
nits
)
Follow-Up
![Page 103: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/103.jpg)
Average Daily Insulin (Units) Taken By Recipients on Insulin Baseline and Post Last InfusionB. Islet After Kidney Recipients
28 4 4 5 2
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
0.0
20.0
40.0
60.0
80.0
100.0A
vera
ge D
aily
Insu
lin U
se (U
nits
)
Follow-Up
![Page 104: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/104.jpg)
Average Daily Insulin (Units/Kg) Taken By Recipients on InsulinBaseline and Post Last Infusion
A. Islet Alone Recipients
232 47 43 28 29
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
0
0.2
0.4
0.6
0.8
1.0
1.2
Ave
rage
Dai
ly In
sulin
Use
(Uni
ts/k
g)
Follow-Up
![Page 105: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/105.jpg)
Average Daily Insulin (Units/Kg) Taken By Recipients on InsulinBaseline and Post Last InfusionB. Islet After Kidney Recipients
27 4 4 5 2
Pre Infusion 1 Month 6 Year 1 Year 2 Year 3
0
0.2
0.4
0.6
0.8
1.0
1.2A
vera
ge D
aily
Insu
lin U
se (U
nits
/kg)
Follow-Up
![Page 106: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/106.jpg)
Percent of Baseline Insulin Used By Recipients on InsulinFollow-Up Post Last Infusion
A. Islet Alone Recipients
48 48 31 29
Month 6 Year 1 Year 2 Year 3
0
50
100
150
Per
cent
of B
asel
ine
Insu
lin
Follow-Up
![Page 107: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/107.jpg)
Percent of Baseline Insulin Used By Recipients on InsulinFollow-Up Post Last Infusion
B. Islet After Kidney Recipients
4 4 5 1
Month 6 Year 1 Year 2 Year 3
0
25
50
75
100
125P
erce
nt o
f Bas
elin
e In
sulin
Follow-Up
![Page 108: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/108.jpg)
Percent of Baseline Insulin at Follow-Up Post Last InfusionIslet Alone Recipients
who Achieved then Lost Insulin Independence
10 24 23 26
Month 6 Year 1 Year 2 Year 3
0
15
30
45
60
75
90
105
120
135
150
Per
cent
of B
asel
ine
Insu
lin
Follow-Up
![Page 109: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/109.jpg)
Percent of Baseline Insulin at Follow-Up Post Last InfusionIslet Alone Recipients
Never Achieving Insulin Independence
33 22 8 3
Month 6 Year 1 Year 2 Year 3
0
15
30
45
60
75
90
105
120
135
150
Per
cent
of B
asel
ine
Insu
lin
Follow-Up
![Page 110: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/110.jpg)
Primary Outcomes Post First InfusionUp to Re-Infusion, Complete Islet Failure, or Last Follow-UpAccording to Pre-Infusion Recipient, Donor, Procurement,
and Islet CharacteristicsIslet Alone Recipients
![Page 111: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/111.jpg)
Primary Outcomes Post First InfusionUp to Re-Infusion, Complete Islet Failure, or Last Follow-UpAccording to Pre-Infusion Recipient, Donor, Procurement,
and Islet CharacteristicsIslet Alone Recipients (continued)
![Page 112: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/112.jpg)
Primary Outcomes Post First InfusionUp to Re-Infusion, Complete Islet Failure, or Last Follow-UpAccording to Pre-Infusion Recipient, Donor, Procurement,
and Islet CharacteristicsIslet Alone Recipients (continued)
![Page 113: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/113.jpg)
Primary Outcomes Post Last InfusionAccording to Pre-Infusion Recipient, Donor,
Procurement, and Islet Characteristics
![Page 114: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/114.jpg)
Primary Outcomes Post Last InfusionAccording to Pre-Infusion Recipient, Donor,
Procurement, and Islet Characteristics (continued)
![Page 115: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/115.jpg)
Primary Outcomes Post Last InfusionAccording to Pre-Infusion Recipient, Donor,
Procurement, and Islet Characteristics (continued)
![Page 116: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/116.jpg)
Primary Outcomes Post Last InfusionAccording to Pre-Infusion Recipient, Donor,
Procurement, and Islet Characteristics (continued)
![Page 117: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/117.jpg)
Fasting Plasma Glucose (mg/dL)Pre Infusion and Post Last Infusion
231 171 52 186 148 84 57
Values greater than 400 mg/dL are not displayed
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
28 19 3 22 16 12 6
Values greater than 400 mg/dL are not displayed
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dLFollow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 118: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/118.jpg)
HbA1C (%)Pre Infusion and Post Last Infusion
233 156 51 177 142 83 57
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
27 18 4 21 16 13 5
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 119: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/119.jpg)
Basal Plasma C-Peptide (ng/mL)Pre Infusion and Post Last Infusion
230 152 46 177 153 94 81
Values greater than 6 ng/ml are not displayed
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
24 17 2 20 14 10 2
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 120: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/120.jpg)
Fasting Plasma Glucose (mg/dL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with One Infusion
66 44 32 14 14
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
![Page 121: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/121.jpg)
HbA1C (%)Pre-Infusion and Post Last Infusion
Islet Alone Recipients with One Infusion
63 42 29 15 14
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
![Page 122: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/122.jpg)
Basal Plasma C-Peptide (ng/mL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with One Infusion
62 41 37 22 25
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
![Page 123: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/123.jpg)
Fasting Plasma Glucose (mg/dL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Two Infusions
117 120 103 83 50 35
Values greater than 400 mg/dL are not displayed
Pre Inf 1 Pre Inf 2 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
![Page 124: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/124.jpg)
HbA1C (%)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Two Infusions
120 110 98 82 48 35
Pre Inf 1 Pre Inf 2 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
![Page 125: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/125.jpg)
Basal Plasma C-Peptide (ng/mL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Two Infusions
118 107 98 84 54 42
Values greater than 6 ng/mL are not displayed
Pre Inf 1 Pre Inf 2 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
![Page 126: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/126.jpg)
Fasting Plasma Glucose (mg/dL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Three Infusions
45 48 49 37 32 20 8
Values greater than 400 mg/dL are not displayed
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
![Page 127: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/127.jpg)
HbA1C (%)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Three Infusions
47 43 48 35 30 20 8
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
![Page 128: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/128.jpg)
Basal Plasma C-Peptide (ng/mL)Pre Infusion and Post Last Infusion
Islet Alone Recipients with Three Infusions
47 42 43 36 31 18 14
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
![Page 129: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/129.jpg)
Fasting Plasma Glucose (mg/dL) Post Last InfusionRecipients Who Ever Achieved Insulin Independence
140 124 110 73 52
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
16 15 12 10 5
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 130: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/130.jpg)
Fasting Plasma Glucose (mg/dL) Post Last InfusionRecipients Who Never Achieved Insulin Independence
70 53 36 11 5
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
9 7 4 2 1
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 131: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/131.jpg)
HbA1C (%) Post Last InfusionRecipients Who Ever Achieved Insulin Independence
145 119 109 73 52
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
16 14 12 10 5
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 132: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/132.jpg)
HbA1C (%) Post Last InfusionRecipients Who Never Achieved Insulin Independence
70 49 31 10 5
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
9 7 4 3 0
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 133: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/133.jpg)
Basal Plasma C-Peptide (ng/mL) Post Last InfusionRecipients Who Ever Achieved Insulin Independence
142 121 109 65 62
C-peptide values greater than 6 are removed for display purposes
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
15 15 12 9 2
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 134: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/134.jpg)
Basal Plasma C-Peptide (ng/mL) Post Last InfusionRecipients Who Never Achieved Insulin Independence
70 47 40 27 17
C-peptide values greater than 6 are removed for display purposes
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
8 5 2 1 0
Pre Inf 1 Month 6 Year 1 Year 2 Year 3
0
1
2
3
4
5
6
ng/m
L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 135: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/135.jpg)
Fasting Plasma Glucose (mg/dL) Pre and Post First Infusion
Insulin Independent Recipients
231 11 25 103 98
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
100
200
300
400
mg/
dL
Follow-Up
28 2 5 9 5
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
100
200
300
400
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 136: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/136.jpg)
Fasting Plasma Glucose (mg/dL) Pre and Post First Infusion
Insulin Dependent Recipients
231 211 203 82 72
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
100
200
300
400
mg/
dL
Follow-Up
28 24 21 13 11
Glucose values greater than 400 mg/dl pre-infusion were removed for display
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
100
200
300
400
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 137: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/137.jpg)
HbA1C (%) Pre and Post First Infusion
Insulin Independent Recipients
233 19 98 92
Pre Inf 1 Day 30 Month 6 Year 1
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
27 3 9 5
Pre Inf 1 Day 30 Month 6 Year 1
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 138: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/138.jpg)
HbA1C (%) Pre and Post First Infusion
Insulin Dependent Recipients
233 125 75 67
Pre Inf 1 Day 30 Month 6 Year 1
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
27 9 10 11
Pre Inf 1 Day 30 Month 6 Year 1
2.5
5.0
7.5
10.0
12.5
%
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 139: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/139.jpg)
Basal Plasma C-Peptide (ng/mL) Pre and Post First Infusion
Insulin Independent Recipients
230 8 23 100 97
C-peptide values greater than 6 ng/mL are removed for presentation
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
1
2
3
4
5
6
ng/m
L
Follow-Up
24 1 4 10 5
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
1
2
3
4
5
6
ng/m
L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 140: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/140.jpg)
Basal Plasma C-Peptide (ng/mL) Pre and Post First Infusion
Insulin Dependent Recipients
230 192 196 76 78
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
1
2
3
4
5
6
ng/m
L
Follow-Up
24 20 20 12 11
Pre Inf 1 Day 7 Day 30 Month 6 Year 1
0
1
2
3
4
5
6
ng/m
L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 141: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/141.jpg)
Recipients with Fasting Blood Glucose 126 mg/dLPost Last Infusion by Insulin Status
A. Islet Alone Recipients
Insulin Status Independent Dependent
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Infusion 1N=0 :231
Month 6N=113 :67
Year 1N=80 :64
Year 2N=41 :40
Year 3N=19 :37
![Page 142: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/142.jpg)
Recipients with Fasting Blood Glucose 126 mg/dLPost Last Infusion by Insulin Status
B. Islet After Kidney Recipients
Insulin Status Independent Dependent
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Infusion 1N=0 :28
Month 6N=12 :9
Year 1N=7 :9
Year 2N=4 :8
Year 3N=0 :5
![Page 143: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/143.jpg)
Insulin Dependent Recipients with Basal C-Peptide 0.5 ng/mL
Post Last InfusionA. Islet Alone Recipients
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=230
Month 6N=65
Year 1N=74
Year 2N=62
Year 3N=62
![Page 144: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/144.jpg)
Insulin Dependent Recipients with Basal C-Peptide 0.5 ng/mL
Post Last InfusionB. Islet After Kidney Recipients
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Inf 1N=24
Month 6N=9
Year 1N=8
Year 2N=8
Year 3N=1
![Page 145: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/145.jpg)
Recipients with HbA1C < 6.5%Post Last Infusion by Insulin Status
A. Islet Alone Recipients
Insulin Status Independent Dependent
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Infusion 1N=0 :233
Month 6N=108 :64
Year 1N=79 :60
Year 2N=40 :40
Year 3N=20 :36
![Page 146: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/146.jpg)
Recipients with HbA1C < 6.5%Post Last Infusion by Insulin Status
B. Islet After Kidney Recipients
Insulin Status Independent Dependent
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
60
70
80
90
100
Pre Infusion 1N=0 :27
Month 6N=11 :9
Year 1N=7 :9
Year 2N=4 :9
Year 3N=1 :4
![Page 147: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/147.jpg)
Pre-Infusion Recipient Lab Summary by Infusion SequenceIslet Alone Recipients
![Page 148: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/148.jpg)
Pre-Infusion Recipient Lab Summary by Infusion SequenceIslet After Kidney Recipients
![Page 149: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/149.jpg)
Metabolic Summary by Follow-Up Post Last InfusionIslet Alone Recipients
![Page 150: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/150.jpg)
Metabolic Summary by Follow-Up Post Last InfusionIslet After Kidney Recipients
![Page 151: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/151.jpg)
Metabolic Summary Post Last Infusion by Insulin StatusIslet Alone Recipients
![Page 152: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/152.jpg)
Secondary Complications of DiabetesPre First Infusion and Post Last Infusion
All Allograft Recipients
![Page 153: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/153.jpg)
Secondary Complications of DiabetesPre First Infusion and Post Last Infusion
All Allograft Recipients (continued)
![Page 154: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/154.jpg)
Secondary Complications of DiabetesPre First Infusion and Post Last Infusion
All Allograft Recipients (continued)
![Page 155: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/155.jpg)
Secondary Complications of DiabetesPre First Infusion and Post Last Infusion
All Allograft Recipients (continued)
![Page 156: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/156.jpg)
Ocular ComplicationsPre First Infusion and Post last Infusion
All Allograft Recipients
![Page 157: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/157.jpg)
Ocular ComplicationsPre First Infusion and Post last Infusion
All Allograft Recipients (continued)
![Page 158: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/158.jpg)
Chapter 6: Liver, Kidney, Lipid and PRA Effects
![Page 159: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/159.jpg)
Incidence of Abnormal Liver Function Testsat Any Scheduled Time Post First Infusion
All Allograft Recipients
and at Month 6, Year 1, Year 2, and Year 3 after the last infusion procedure occurs.Lab values analyzed in this Exhibit are taken prior to each subsequent infusion
>=3X ULN2-3X ULN1-2X ULN
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
ALT AST Alkaline Phosphatase Total Bilirubin
![Page 160: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/160.jpg)
ALT (IU/L) Pre Infusion and Post Last Infusion
243 170 54 174 136 75 53
Values greater than 150 IU/L are removed for display
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
25
50
75
100
125
150
IU/L
Follow-Up
29 20 2 22 16 13 5
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
25
50
75
100
125
150
IU/L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 161: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/161.jpg)
AST (IU/L) Pre Infusion and Post Last Infusion
243 170 54 174 136 75 53
Values greater than 120 IU/L are removed for display
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
20
40
60
80
100
120
IU/L
Follow-Up
29 20 2 22 16 13 5
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
20
40
60
80
100
120
IU/L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 162: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/162.jpg)
Alkaline Phosphatase (IU/L) Pre Infusion and Post Last Infusion
238 166 52 169 136 76 53
Values greater than 350 IU/L are removed for display
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
IU/L
Follow-Up
27 20 2 22 16 13 5
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
IU/L
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 163: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/163.jpg)
Total Bilirubin (mg/dL) Pre Infusion and Post Last Infusion
239 169 53 168 136 76 50
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mg/
dL
Follow-Up
29 20 2 22 16 13 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 164: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/164.jpg)
Incidence of Abnormal Lipid Testsat Any Scheduled Time Post First Infusion
All Allograft Recipients
and at Month 6, Year 1, Year 2, and Year 3 after the last infusion procedure occurs.Lab values analyzed in this Exhibit are taken prior to each subsequent infusion
2-3X ULN1-2X ULN
Per
cent
of R
ecip
ient
s
0
10
20
30
40
50
Total Cholesterol Triglycerides
![Page 165: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/165.jpg)
Total Cholesterol (mg/dL) Pre Infusion and Post Last Infusion
237 147 47 164 143 81 55
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
mg/
dL
Follow-Up
27 12 1 19 15 13 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 166: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/166.jpg)
HDL (mg/dL) Pre Infusion and Post Last Infusion
234 137 42 162 141 79 55
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
25
50
75
100
125
150
mg/
dL
Follow-Up
27 12 1 18 15 13 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
25
50
75
100
125
150
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 167: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/167.jpg)
LDL (mg/dL) Pre Infusion and Post Last Infusion
234 137 41 161 141 79 55
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
mg/
dL
Follow-Up
27 12 1 18 15 13 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 168: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/168.jpg)
Triglycerides (mg/dL) Pre Infusion and Post Last Infusion
237 146 47 164 143 81 55
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
450
mg/
dL
Follow-Up
27 12 1 19 15 13 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
300
350
400
450
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 169: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/169.jpg)
Incidence of Increase in Serum Creatinine (mg/dL) Greater than 0.5 from Baseline
at Any Scheduled Time Post First InfusionAll Allograft Recipients
and at Month 6, Year 1, Year 2, and Year 3 after the last infusion procedure occurs.Lab values analyzed in this Exhibit are taken prior to each subsequent infusion
>1.0 mg/dL increase from baseline0.5 - 1.0 mg/dL increase from baseline
Perc
ent o
f Rec
ipie
nts
0
10
20
30
40
50
Islet Alone Islet After Kidney
![Page 170: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/170.jpg)
Serum Creatinine (mg/dL) Pre Infusion and Post Last Infusion
245 173 54 182 151 88 59
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mg/
dL
Follow-Up
30 19 3 22 16 12 6
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mg/
dL
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 171: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/171.jpg)
Calculated Creatinine Clearance (mL/min/1.73m2)Pre Infusion and Post Last Infusion
193 90 23 99 94 28 15
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
mL/
min
/1.7
3m2
Follow-Up
17 5 0 9 11 7 3
PreInf 1
PreInf 2
PreInf 3
Month 6 Year 1 Year 2 Year 3
0
50
100
150
200
250
mL/
min
/1.7
3m2
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 172: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/172.jpg)
GFR (mL/min/1.73m2)Pre Infusion and Post Last Infusion
245 173 54 185 152 88 59
Four values greater than 180 ml/min/1.73 m2 have been removed for display
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
30
60
90
120
150
180
ml/m
in/1
.73
m2
Follow-Up
30 19 3 22 16 12 6
One Value greater than 180 ml/min/1.73 m2 has been removed for display
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
30
60
90
120
150
180
ml/m
in/1
.73
m2
Follow-Up
A. Islet Alone Recipients B. Islet After Kidney Recipients
![Page 173: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/173.jpg)
Class I PRA (%)Pre Infusion and Post Last Infusion
Islet Alone Recipients
214 147 45 104 79 51 32
Pre Inf 1 Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
0
10
20
30
40
50
60
70
80
90
100
%
Follow-Up
![Page 174: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/174.jpg)
Change in Class I PRA from Pre First InfusionPre Subsequent Infusion and Post Last Infusion
Islet Alone Recipients
136 42 99 74 48 28
Pre Inf 2 Pre Inf 3 Month 6 Year 1 Year 2 Year 3
-25
0
25
50
75
100
Cha
nge
from
Pre
Infu
sion
1
Follow-Up
![Page 175: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/175.jpg)
Class I PRA Post Last InfusionIslet Alone Recipients with Complete Graft Loss
4 6 7 3
Month 6 Year 1 Year 2 Year 3
0
10
20
30
40
50
60
70
80
90
100
%
Follow-Up
![Page 176: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/176.jpg)
Class I PRA Post Last InfusionIslet Alone Recipients without Complete Graft Loss
100 73 44 29
Month 6 Year 1 Year 2 Year 3
0
10
20
30
40
50
60
70
80
90
100
%
Follow-Up
![Page 177: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/177.jpg)
Chapter 7: Adverse Events
![Page 178: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/178.jpg)
Percent of Recipients with an Adverse Event (AE) or Serious Adverse Event (SAE)
in Year 1 Post First Infusion
![Page 179: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/179.jpg)
Total Number of Adverse Events and Serious Adverse Events
in Year 1 Post First Infusion
![Page 180: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/180.jpg)
Percent of Recipients with a Serious Adverse Eventin Year 1 Post First Infusion by Year of First Infusion
All Allograft Recipients
Any SAESAE related to either the infusion procedure or immunosupressionSAE related to the infusion procedureSAE related to immunosupression
Per
cent
of R
ecip
ient
s
0
10
20
30
40
50
60
Year of First Infusion1999N=6
2000N=12
2001N=35
2002N=69
2003N=39
2004N=46
2005N=51
![Page 181: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/181.jpg)
Serious Adverse Event Type by Relatedness to Islet Infusion or Immunosuppression
![Page 182: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/182.jpg)
Outcome of Serious Adverse Events by Relatedness to Islet Infusion or Immunosuppression
![Page 183: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/183.jpg)
Serious Adverse Events MedDRA System/Organ Classby Relatedness to Islet Infusion or Immunosuppression
![Page 184: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/184.jpg)
Serious Adverse Events MedDRA System/Organ Classby Relatedness to Islet Infusion or Immunosuppression
(continued)
![Page 185: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/185.jpg)
Most Common Serious Adverse EventsIslet Alone Recipients
![Page 186: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/186.jpg)
Most Common Serious Adverse EventsIslet After Kidney Recipients
![Page 187: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/187.jpg)
Most Common Serious Adverse Events Reported Within One Year of Any Infusion
All Allograft Recipients
![Page 188: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/188.jpg)
Most Common Serious Adverse Events Reported More than One Year after Any Infusion
All Allograft Recipients
![Page 189: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/189.jpg)
Summary of Reported Neoplasms
![Page 190: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/190.jpg)
Listing of Reported Hemorrhages and Portal Vein Thromboses
All Allograft Recipients
![Page 191: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/191.jpg)
Listing of Reported Hemorrhages and Portal Vein Thromboses
All Allograft Recipients (continued)
![Page 192: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/192.jpg)
Listing of Reported Hemorrhages and Portal Vein Thromboses
All Allograft Recipients (continued)
![Page 193: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/193.jpg)
Number of Days Hospitalized at Infusion (from Admission to Discharge)
by Infusion SequenceIslet Alone Recipients
243 170 48
1 2 3
0
5
10
15
20
Num
ber o
f Day
s
Infusion Sequence
![Page 194: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/194.jpg)
Number of Days Hospitalized at Infusion (from Admission to Discharge)
by Infusion SequenceIslet After Kidney Recipients
29 20 3
1 2 3
0
5
10
15
20
Num
ber o
f Day
s
Infusion Sequence
![Page 195: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/195.jpg)
Hospitalization Experienced Post Last Infusion by Total Number of Infusions Received
Islet Alone Recipients
![Page 196: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/196.jpg)
Hospitalization Experienced Post Last Infusion by Total Number of Infusions Received
Islet After Kidney Recipients
![Page 197: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/197.jpg)
Chapter 8: Registry Data Quality Review
![Page 198: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/198.jpg)
Expected and Submitted Forms by Infusion SequenceAll Allograft Recipients
![Page 199: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/199.jpg)
Expected and Submitted Follow-Up Forms Post Last infusion
All Allograft Recipients
![Page 200: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/200.jpg)
Extent of Follow-Up Post Last InfusionAll Allograft Recipients
![Page 201: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/201.jpg)
CITR Coordinating Center(July 2006 – July 2007)
PI: Franca Barton
Co-PI: Donald Stablein
Matthew Beyers
Bryan Calaway
Yamini Damodharan
Krista Huang
Jessica Long
Glenn Tucker
Chuck Wagner
Steve Wease
![Page 202: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/202.jpg)
CITR Committees
Scientific Advisory Committee (SAC)
Compliance Committee
Data Elements Committee
Publications/Presentations Committee
Transplant Coordinators’/Data Managers’ Committee
![Page 203: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/203.jpg)
CITR Scientific Advisory Committee (SAC)
Chair: Bernhard J. Hering
Michael Cecka
Philip Cryer
Mary D. Ellison
Olle Korsgren
Jerry P. Palmer
Camillo Ricordi
![Page 204: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/204.jpg)
CITR Compliance Committee
Michael Appel
Parastoo Dinyari
E. Brian Flanagan
Fouad Kandeel
Eileen M. Markmann
Jamen Parkey
Marti Sears
Elyse Stuart
![Page 205: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/205.jpg)
CITR Data Elements Committee
Chair: Marc Garfinkel
David Baidal
Enrico Cagliero
Fouad Kandeel
Dixon Kaufman
Melissa Roberts
Marti Sears
![Page 206: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/206.jpg)
CITR Publications/Presentations Committee
Chair: Rodolfo Alejandro
Michael Appel
Nancy Bridges
Elizabeth Holbrook
Ali Naji
Bashoo Naziruddin
Craig Smith
![Page 207: CITR Annual Report Exhibits](https://reader036.vdocuments.us/reader036/viewer/2022062501/56816167550346895dd0f298/html5/thumbnails/207.jpg)
CITR Transplant Coordinators’/Data Managers’ Committee
Chair: Melissa Roberts
Jarrett Anderson
Shama Bader
David Baidal
LeAnn Batterson
Jennifer Bishop
Parastoo Dinyari
Jane Fasbender
Beverly Fleckton
Charlotte Garwood
Susan George
Debbie Grice
Darrell Grimes
Jeannette Hacker
Michael Hanschew
Celia Hartigan
Nancy Radke
Violeta Raverdy
Marilyn Reeve
Payam Salehi
Ammar Saoud
Grace Sauzier
Marti Sears
Jill Sheedy
KD Shiang
Elyse Stuart
Joanna Sung
Pat Swanson
Shameka Thomas
Heather Turgeon
Piotr Witkowski
Robin Jevne
Jenny Joseph
Debra Kemp
Carol Kramer
Arlene LaRose
Mark Lockwood
Eileen Markmann
Joan Martellotto
Marli McCulloch-Olson
Joan McElroy
Melissa McGraw
Suzanne Miller
Bashoo Naziruddin
Lori Otken
Maral Palanjian
Jamen Parkey